Business
Issue of New Ordinary Shares and TVR
Issue of New Ordinary Shares and TVR.
About this update from Kanabo Group Plc
[{"type":"text","content":"\n\n\n10 July 2023\nKanabo Group PLC\n(\"Kanabo\" or the \"Company\")\nIssuance of New Ordinary Shares and Total Voting Rights\nFollowing the Company's publication of the prospectus, announced on 13 June 2023 (\"The Prospectus\"), the 38,461,492 ordinary shares issued (\"2020 Deferred Consideration Shares\") in connection with the acquisition of Kanabo Research Limited at a price of 6.5p, have been admitted today, 10 July 2023, to the Standard List of the London Stock Exchange (\"Admission\")\nFollowing Admission, for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Kanabo announces that the Company has 611,677,871 ordinary shares of 2.5p each in issue (\"Ordinary Shares\"), each share carrying the right to one vote. The figure of 611,677,871 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nThe Directors of the Company accept responsibility for the contents of this announcement.\nFor further information, please visit http://www.kanabogroup.com/ or contact the following:\nEnquiries:\n \n\n\n\nKanabo Group plc\nAvihu Tamir, Chief Executive Officer\nAssaf Vardimon, Chief Financial Officer\nIan Mattioli, Non-Executive Chair of the Board\n \n\n\nvia Vigo Consulting\n+44 (0)20 7390 0230\n\n\n\n\nPeterhouse Capital Ltd (Financial Adviser and Broker)\nEran Zucker/ Lucy Williams / Charles Goodfellow\n \n\n\n+44 (0)20 7469 0930\n\n\n\n\nVigo Consulting (Financial Public Relations/Investor Relations)\nJeremy Garcia / Fiona Hetherington / Verity Snow\[email protected]\n\n\n +44 (0)20 7390 0230\n \n\n\n\n \n \nAbout Kanabo Group Plc\nKanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.\n&nbs...